Drug Search Results
More Filters [+]

Laropiprant

Alternative Names: laropiprant, mk-0524b, mk-0524, mk0524, mk 0524
Latest Update: 2023-08-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CRTH2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Laropiprant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Hyperlipoproteinemias|Dyslipidemia|Hyperlipidemia|Type 2 Diabetes|Hypercholesterolemia|Myocardial Ischemia|Coronary Artery Disease|Atherosclerosis|Inflammation|Oxidative Stress

Phase 3: Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Hyperlipoproteinemia Type V|Hyperlipoproteinemias|Hyperlipidemia|Lipidoses|Coronary Artery Disease|Coronary Disease|Hyperlipoproteinemia Type II|Myocardial Infarction|Peripheral Arterial Disease|Stroke|Intermittent Claudication|Myocardial Ischemia|Peripheral Vascular Diseases

Phase 2: Dyslipidemia|Asthma|Hypercholesterolemia|Rhinitis, Allergic, Seasonal|Flushing

Phase 1: Type 2 Diabetes|Dyslipidemia|Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemia Type II|Rosacea

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NILACH

P4

Terminated

Atherosclerosis

2014-07-01

MK-0524A-119

N/A

Terminated

Dyslipidemia|Hypercholesterolemia

2013-05-01

MK-0524A-133

P3

Terminated

Hypercholesterolemia|Dyslipidemia

2013-02-26

2010-019954-42

P4

Terminated

Unknown

2013-01-18

Recent News Events